share_log

Arcutis Biotherapeutics | UPLOAD: Others

Arcutis Biotherapeutics | UPLOAD: Others

Arcutis Biotherapeutics | UPLOAD:其他
美股SEC公告 ·  01/23 14:37

Moomoo AI 已提取核心訊息

Arcutis Biotherapeutics, Inc. received comments from the United States Securities and Exchange Commission (SEC) regarding its Schedule TO-I filing on January 16, 2024. The SEC's letter, dated January 23, 2024, addressed to Todd Franklin Watanabe, the President and CEO of Arcutis, highlighted concerns over certain conditions in the company's Offer to Exchange. The SEC requested revisions to narrow or qualify broad conditions that could potentially lead to illusory offer concerns under Section 14(e) of the Exchange Act and Regulation 14E. Specifically, the SEC pointed out conditions related to general market suspensions, limitations on securities prices, governmental or regulatory limitations on credit extension, and the impact of wars or crises involving the United States. The SEC also noted a discrepancy in the timing...Show More
Arcutis Biotherapeutics, Inc. received comments from the United States Securities and Exchange Commission (SEC) regarding its Schedule TO-I filing on January 16, 2024. The SEC's letter, dated January 23, 2024, addressed to Todd Franklin Watanabe, the President and CEO of Arcutis, highlighted concerns over certain conditions in the company's Offer to Exchange. The SEC requested revisions to narrow or qualify broad conditions that could potentially lead to illusory offer concerns under Section 14(e) of the Exchange Act and Regulation 14E. Specifically, the SEC pointed out conditions related to general market suspensions, limitations on securities prices, governmental or regulatory limitations on credit extension, and the impact of wars or crises involving the United States. The SEC also noted a discrepancy in the timing of the announcement for an offer extension, advising compliance with Rule 14e-1(d) which requires announcements to be made no later than 9:00 a.m. Eastern time. Arcutis is responsible for the accuracy and adequacy of their disclosures and has been instructed to respond to the SEC's comments with the requested revisions or provide a rationale for why the comments may not apply to their situation.
Arcutis Biotherapeutics, Inc.收到了美國證券交易委員會(SEC)關於其於2024年1月16日提交的附表TO-I的評論。美國證券交易委員會於2024年1月23日致Arcutis總裁兼首席執行官渡邊託德·富蘭克林的信強調了對該公司交易要約中某些條件的擔憂。根據《交易法》第14(e)條和第14E條,美國證券交易委員會要求進行修訂,以縮小或限定可能導致虛幻報價擔憂的廣泛條件。具體而言,美國證券交易委員會指出了與普遍市場暫停、證券價格限制、政府或監管機構對信貸延期的限制以及涉及美國的戰爭或危機的影響相關的情況。美國證券交易委員會還注意到宣佈延期要約的時間存在差異,建議遵守第14e-1(d)條,該規則要求在美國東部時間上午9點之前發佈公告。Arcutis對其披露的準確性和充分性負責,並已被指示對美國證券交易委員會的評論做出回應,並按要求進行修訂,或提供理由,說明這些評論可能不適用於他們的情況。
Arcutis Biotherapeutics, Inc.收到了美國證券交易委員會(SEC)關於其於2024年1月16日提交的附表TO-I的評論。美國證券交易委員會於2024年1月23日致Arcutis總裁兼首席執行官渡邊託德·富蘭克林的信強調了對該公司交易要約中某些條件的擔憂。根據《交易法》第14(e)條和第14E條,美國證券交易委員會要求進行修訂,以縮小或限定可能導致虛幻報價擔憂的廣泛條件。具體而言,美國證券交易委員會指出了與普遍市場暫停、證券價格限制、政府或監管機構對信貸延期的限制以及涉及美國的戰爭或危機的影響相關的情況。美國證券交易委員會還注意到宣佈延期要約的時間存在差異,建議遵守第14e-1(d)條,該規則要求在美國東部時間上午9點之前發佈公告。Arcutis對其披露的準確性和充分性負責,並已被指示對美國證券交易委員會的評論做出回應,並按要求進行修訂,或提供理由,說明這些評論可能不適用於他們的情況。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息